Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant after renal transplantation. Withdrawal of sirolimus from the immunosuppression regimen may reduce B-cell surveillance. We present a case of rapidly progressive central nervous system (CNS) polymorphic Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disorder following the withdrawal of sirolimus
The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for transplantat...
Posttransplant lymphoproliferative disorder (PTLD) occurs in 1% to 3% of adult renal transplant reci...
Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid ...
Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant afte...
Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant ...
Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid orga...
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantatio...
A 43-year-old female developed an EpsteinBarr virus (EBV)-positive post-transplant lymphoproliferati...
Introduction. Post-transplant lymphoproliferative disorder (PTLD) is one of the most severe and ofte...
Background: Post-transplant lymphoproliferative disorders (PTLD) are rare immunosuppression complica...
Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of diseases characteriz...
Tacrolimus is an immunosuppressive agent that can show a wide variety of neurological side effects, ...
Introduction: Primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD...
Post-transplant lymphoproliferative disorder (PTLD) is a rare complication seen in hematologic stem ...
Generalized lymphedema is an extremely rare effect of sirolimus therapy in renal transplant recipien...
The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for transplantat...
Posttransplant lymphoproliferative disorder (PTLD) occurs in 1% to 3% of adult renal transplant reci...
Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid ...
Sirolimus, a potent inhibitor of B- and T-cell activation. is a commonly used immunosuppressant afte...
Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR), used as an immunosuppressant ...
Posttransplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of solid orga...
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of organ transplantatio...
A 43-year-old female developed an EpsteinBarr virus (EBV)-positive post-transplant lymphoproliferati...
Introduction. Post-transplant lymphoproliferative disorder (PTLD) is one of the most severe and ofte...
Background: Post-transplant lymphoproliferative disorders (PTLD) are rare immunosuppression complica...
Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of diseases characteriz...
Tacrolimus is an immunosuppressive agent that can show a wide variety of neurological side effects, ...
Introduction: Primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD...
Post-transplant lymphoproliferative disorder (PTLD) is a rare complication seen in hematologic stem ...
Generalized lymphedema is an extremely rare effect of sirolimus therapy in renal transplant recipien...
The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for transplantat...
Posttransplant lymphoproliferative disorder (PTLD) occurs in 1% to 3% of adult renal transplant reci...
Mammalian target of rapamycin (mTOR) inhibitors have been shown to reduce proliferation of lymphoid ...